← Back to headlines
Unicycive Aims to Differentiate OLC in Hyperphosphatemia Market
Unicycive is working to distinguish its drug OLC within the competitive chronic kidney disease (CKD) hyperphosphatemia market.
22 Jun, 13:56 — 22 Jun, 13:56
Sources
Showing 1 of 1 sources
Related Stories
Homeland Security Secretary’s Plane Makes Emergency Landing After Engine Failure
24m ago
Berkshire Hathaway Signals Long-Term Commitment to Japanese Trading Houses
34m ago
South Korean Utility Proposes $15 Billion Upfront Power Payment From Samsung
55m ago
Chevron Confirms Expansion of Oil Operations in Venezuela
1h ago